Dr. Paul W. Conrad, MD PHD
Ophthalmology (Ophthalmology Physician)
- Medicare participating
At a glance
- Years since graduation
- 22
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 651
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
PA license MD439710 · MI license 4301085989 · WV license 31533
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- UPMC Mercy Pittsburgh, PA
Medical groups
- Retina Vitreous Consultants Inc. (8 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 651
- Services billed
- 22,681
- Patients’ average age
- 78
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 4,260 | 22 |
| Injection, aflibercept, 1 mg | 1,556 | 187 |
| Injection of drug into eye | 1,026 | 298 |
| Imaging of retina | 888 | 439 |
| Established patient office or other outpatient visit, 20-29 minutes | 665 | 343 |
| Compounded drug, not otherwise classified | 294 | 120 |
| New patient office or other outpatient visit, 45-59 minutes | 129 | 129 |
| Photography of the retina | 33 | 31 |
| Unclassified drugs | 30 | 15 |
| Established patient office or other outpatient visit, 30-39 minutes | 30 | 30 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in Monroeville, PA | 162 |
| Brimonidine Tartrate Other prescribers in Monroeville, PA | 107 |
| Ketorolac Tromethamine Other prescribers in Monroeville, PA | 84 |
| Latanoprost Other prescribers in Monroeville, PA | 69 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Monroeville, PA | 67 |
| Timolol Maleate Other prescribers in Monroeville, PA | 33 |
| Lumigan (bimatoprost) Other prescribers in Monroeville, PA | 15 |
| Dorzolamide Hcl Other prescribers in Monroeville, PA | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $5,517 in research payments for these studies, mostly to the institutions running them.
- Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease
Regeneron Pharmaceuticals, Inc. · Completed · NCT04429503
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.